These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8973990)

  • 1. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
    Sambol NC; Chiang J; O'Conner M; Liu CY; Lin ET; Goodman AM; Benet LZ; Karam JH
    J Clin Pharmacol; 1996 Nov; 36(11):1012-21. PubMed ID: 8973990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.
    Cusi K; Consoli A; DeFronzo RA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4059-67. PubMed ID: 8923861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
    Barrington P; Chien JY; Showalter HD; Schneck K; Cui S; Tibaldi F; Ellis B; Hardy TA
    Diabetes Obes Metab; 2011 May; 13(5):426-33. PubMed ID: 21251178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.
    Abbasi F; Kamath V; Rizvi AA; Carantoni M; Chen YD; Reaven GM
    Diabetes Care; 1997 Dec; 20(12):1863-9. PubMed ID: 9405908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
    Buse JB; DeFronzo RA; Rosenstock J; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetes Care; 2016 Feb; 39(2):198-205. PubMed ID: 26285584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.
    Jeppesen J; Zhou MY; Chen YD; Reaven GM
    Diabetes Care; 1994 Oct; 17(10):1093-9. PubMed ID: 7821127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food.
    Ericsson H; Sjöberg F; Heijer M; Dorani H; Johansson P; Wollbratt M; Norjavaara E
    Diabetes Res Clin Pract; 2012 Dec; 98(3):436-44. PubMed ID: 23010558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study.
    Kudolo GB; Wang W; Javors M; Blodgett J
    Clin Nutr; 2006 Aug; 25(4):606-16. PubMed ID: 16698134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
    Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
    Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of piragliatin, a glucokinase activator, on fasting and postprandial plasma glucose in patients with type 2 diabetes mellitus.
    Zhi J; Zhai S
    J Clin Pharmacol; 2016 Feb; 56(2):231-8. PubMed ID: 26183686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.
    Schmitt C; Portron A; Jadidi S; Sarkar N; DiMarchi R
    Diabetes Obes Metab; 2017 Oct; 19(10):1436-1445. PubMed ID: 28730694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-dose, crossover study comparing the pharmacokinetics and pharmacodynamics of 2 formulations of metformin in healthy volunteers.
    Noh YH; Lim HS; Jung JA; Jin SJ; Kim MJ; Kim YH; Park HJ; Bae KS
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):605-13. PubMed ID: 22762856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of metformin on intact proinsulin and des 31,32 proinsulin concentrations in subjects with non-insulin-dependent (type 2) diabetes mellitus.
    Nagi DK; Ali VM; Yudkin JS
    Diabet Med; 1996 Aug; 13(8):753-7. PubMed ID: 8862952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A; Jadidi S; Sarkar N; DiMarchi R; Schmitt C
    Diabetes Obes Metab; 2017 Oct; 19(10):1446-1453. PubMed ID: 28741871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control.
    Reaven GM; Johnston P; Hollenbeck CB; Skowronski R; Zhang JC; Goldfine ID; Chen YD
    J Clin Endocrinol Metab; 1992 May; 74(5):1020-6. PubMed ID: 1569149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers.
    Lee SH; Kwon KI
    Arch Pharm Res; 2004 Jul; 27(7):806-10. PubMed ID: 15357011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.